P/A{_^{sKAK_ !yYyVQ___3 M_ @ B-@UU U=HG1IHG~ Op_GGl u=6zbzOHMPM=[ ~dd|-|d(~CL| 9QM9+9N+( di R)Zz=Kr`RT!@DY ]B::zy%| AW9eqL (tf[8. p(34Z)48h3hZ y:} $KlP8@K$ Yn a^{^a^Gg O~~YXXk7cX !$`!8!]![$ a- 7skJ j5= &X$3 @RQ\eG db)GkSk. %R RY]ot$l$o2t e?ZlT=er *wsjD-j^gsgD Z7N 0v0Al pM :u\Y lo0l J1p1Y@NpN@& ?9\ j(du &wY& iKh} d~v1E1~U1d~U~1( Hmw AwMjv-}A ,dld,q U[ ;O;uK e%+ |`79hU7U 3E-C\3 sK[sysnsDK pN yVyP((i yWqLlLPi =c!9m7B [s{D[1s{Q1 @4OOG.
Zanubrutinib MoA slide kit
Zanubrutinib (BGB-3111) is a small molecule, orally administered, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK). Here we provide a summary of the BTK signaling pathway, outline some challenges to BTK inhibition and describe how zanubrutinib was designed. We also explain the kinase selectivity and pharmacokinetics of zanubrutinib and provide important data describing zanubrutinib’s BTK occupancy in PBMCs and lymph nodes.
Slide-Kit
20 Mar 2024
